Page 28 - Read Online

Page 4 of 8 De Luca et al. Mini-invasive Surg 2022;6:13 https://dx.doi.org/10.20517/2574-1225.2021.127

Table 1. Perioperative, pathological and follow up variables of the sRARP group
Total
n patients 11
Age, mean (SD), years 72.6 (3.2)
BMI, mean (SD) 25.1 (1.6)
Pre-HIFU PSA, ng/dL; mean (SD) 9.1 (2.3)
Pre-HIFU Gleason score, number (%)
• 6 5 (45.5)
• 7 (3 + 4) 4 (36.3)
• 7 (4 + 3) 2 (18.1)
Pre-RT risk; N° (%)
• Low 5 (45.5)
• Intermediate 6 (55.5)
Pre-sRARP PSA, ng/dL; mean (SD) 3.6 (2.0)
Pre-sRARP prostate volume, CC; mean (SD) 37.9 (13.3)
Pre-sRARP IPSS; median (IQR) 10 (6.32-13.3)
Pre-sRARP QoL; media (IQR) 3 (0-4)
Pre-sRARP IIEF; median (IQR) 16 (11-23)
Pre-sRARP mpMRI, PiRads; n (%)
• 3 2 (18.1)
• 4 6 (54.5)
• 5 3 (27.2)
Operative time, min; mean (SD) 110 (25.8)
Catheterization time, days; median (IQR) 5 (4-7)
Hospital stay, days; median (IQR) 6 (6-8)
Postoperative complications according to Clavien Dindo, n (%)
• Grade 1:
○ Fever 1 (0)
○ Asymptomatic lymphocele 1 (0)
Post-sRARP Gleason score, number (%)
• 6 2 (18.1)
• 7 (3 + 4) 6 (55.5)
• 7 (4 + 3) 3 (27.2)
Positive SM, number (%) 3 (27.2)
Pathological stage, number (%)
• pT2 8 (72.7)
• pT3 3 (2.2)
Numbers of lymph node removed; mean (SD) 23.3 (6.3)
Pathological N1, number (%) 0 (0)
Post-sRARP PSA, ng/dL; mean (SD)
• 1 month 0.02 (0.01)
• 3 months 0.01 (0.01)
• 6 months 0.03 (0.02)
• 12 months 0.2 (0.01)
Post-sRARP continence rate; number (%)
• 1 month 4 (36.3)
• 3 months 5 (45.5)
• 6 months 7 (63.6)
• 12 months 9 (81.1)
Post-sRARP potency rate; number (%)
• 1 month 0 (0)
• 3 months 0 (0)
• 6 months 1 (9.0)
• 12 months 2 (18.1)

BMI: Body mass index; SD: standard deviation; PSA: prostate specific antigen; IQR: interquartile range; IPSS: international prostate symptoms
score; IIEF: international index of erectile function; QoL: quality of life; mpMRI: multiparametric magnetic resonance imaging; PiRADS: prostate
imaging reporting and data system; sRARP: salvage robot assisted radical prostatectomy; SM: surgical margins.